Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galera Therapeutics, Inc. - Common Stock (NQ: GRTX )

0.1450 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Galera Therapeutics, Inc. - Common Stock

Galera Therapeutics completes acquisition of Nova Pharmaceuticals
From Galera Therapeutics
Via GlobeNewswire
Galera Announces Board Approval of Complete Liquidation and Dissolution
Company reports second quarter 2024 financial results 
From Galera Therapeutics
Via GlobeNewswire
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value 
From Galera Therapeutics
Via GlobeNewswire
Galera Adopts Limited Duration Stockholder Rights Agreement
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value 
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
From Galera Therapeutics
Via GlobeNewswire
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
From Galera Therapeutics
Via GlobeNewswire
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
From Galera Therapeutics
Via GlobeNewswire
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy 
From Galera Therapeutics
Via GlobeNewswire
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Galera Therapeutics
Via GlobeNewswire
Galera Expands Commercial Leadership Team
From Galera Therapeutics
Via GlobeNewswire
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
From Galera Therapeutics
Via GlobeNewswire
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
From Galera Therapeutics
Via GlobeNewswire
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients 
From Galera Therapeutics
Via GlobeNewswire
Galera to Present at Piper Sandler Annual Healthcare Conference
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics
Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.